NG2-73 - A Novel Agent For The Treatment of Insomnia

 

Key Data:

Drug (Brand/Generic)
NG2-73
Company/Licensee
Neurogen
Therapy Class
GABA partial agonist
Product Description
A selective, partial GABA alpha-3 agonist
Current Indication
Treatment of insomnia
Market Sector
CNS
Development Status
Phase II completed, Phase II/III trials suspended



Home
New On This Site
Products & Services
Company A-Z
Industry Projects
Features
White Papers
Jobs & Careers
Industry News
Gallery
Events & Exhibitions
Newsletter
Advertise With Us
About Us
Client Area


RSS What is RSS
For every phase of your drug development